ReadyCell presents the final reporting period of the SEGURAM project
The final presentation highlighted the potential of gut-on-a-chip technology to advance bioavailability and efficacy testing in the meat industry.
3DLIVER: Celebrating one year of progress in the project for advanced drug toxicity testing and discovery
The main aim of the 3DLIVER project is the generation of innovative human liver-derived 3D in vitro models as innovative ready-to-use kits for drug testing models, using human liver cells and extracellular matrix (ECM), to generate more reliable in vitro drug testing devices.
Japanese distributor OYC meets with ReadyCell in Barcelona
The meeting focused on exploring the current market dynamics and emerging trends in the field of cell culture technology and drug discovery. Both companies, ReadyCell and OYC, are committed to providing their customers with top-tier products and services.
3DLIVER: Innovative Human-Derived 3D Liver Models for Drug Toxicity Testing and Discovery
The main objective of this project is to develop novel 3D in vitro tools derived from the human liver, relevant to the discovery and preclinical phases of drug development.
Adari Cell visits ReadyCell’s facilities in Barcelona
The U.S. company Adari Cell Science met with ReadyCell at the Parc Científic de Barcelona and shared their impressions of the past year.
Stretchbio holds a meeting in Denmark to evaluate the first 12 months of the project
Readycell participated in the annual meeting of the StretchBio Project, which was held at the Danmarks Tekniske Universitet (DTU) in Copenhagen.
